Drug Profile
Acotiamide - Astellas Pharma/Zeria
Alternative Names: Acofide; Acotiamide hydrochloride hydrate; YM 443; Z-338; ZG-802Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Zeria
- Developer Astellas Pharma; Zeria
- Class Benzamides; Gastrokinetics; Small molecules; Thiazoles
- Mechanism of Action Acetylcholine stimulants; Acetylcholinesterase inhibitors; Muscarinic M1 receptor antagonists; Muscarinic M2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-ulcer dyspepsia
- Phase II Helicobacter infections
Most Recent Events
- 02 Jan 2023 Phase-II development for Non-ulcer dyspepsia (In children, In adolescents) is ongoing in Japan (PO) (NCT04526119)
- 24 Dec 2020 Phase-III clinical trials in Non-ulcer dyspepsia (In children, In adolescents) in Japan (PO) (NCT04526119)
- 25 Aug 2020 Zeria Pharmaceutical plans a phase III trial for Non-ulcer dyspepsia in Japan, in October 2020 (NCT04526119)